 Connection
Charles Dinarello to Peritoneal Dialysis, Continuous Ambulatory
This is a "connection" page, showing publications Charles Dinarello has written about Peritoneal Dialysis, Continuous Ambulatory.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.328 |
|
|
|
-
Dinarello CA. Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Nephrol Dial Transplant. 1995; 10 Suppl 3:25-8.
Score: 0.121
-
Shaldon S, Koch KM, Quellhorst E, Lonnemann G, Dinarello CA. CAPD is a second-class treatment. Contrib Nephrol. 1985; 44:163-72.
Score: 0.061
-
Shaldon S, Koch KM, Quellhorst E, Dinarello CA. Pathogenesis of sclerosing peritonitis in CAPD. Trans Am Soc Artif Intern Organs. 1984; 30:193-4.
Score: 0.057
-
Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994 Mar; 45(3):890-6.
Score: 0.029
-
Pereira BJ, Poutsiaka DD, King AJ, Strom JA, Narayan G, Levey AS, Dinarello CA. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int. 1992 Dec; 42(6):1419-24.
Score: 0.026
-
Shaldon S, Dinarello CA, Wyler DJ. Induction of interleukin-1 during CAPD. Contrib Nephrol. 1987; 57:207-12.
Score: 0.017
-
Dinarello CA, Krueger JM. Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. Fed Proc. 1986 Oct; 45(11):2545-8.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|